LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

Bio-Techne Corp

Cerrado

SectorSanidad

59.29 1.39

Resumen

Variación precio

24h

Actual

Mínimo

57.49

Máximo

59.67

Métricas clave

By Trading Economics

Ingresos

-176K

38M

Ventas

9.3M

296M

P/B

Media del Sector

113.076

110.024

Rentabilidad por dividendo

0.54

Margen de beneficios

12.846

Empleados

3,100

EBITDA

-135K

78M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+21.99% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.54%

2.26%

Próximas Ganancias

6 may 2026

Fecha Próximo Dividendo

27 feb 2026

Próxima Fecha de Ex Dividendo

18 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-791M

9.4B

Apertura anterior

57.9

Cierre anterior

59.29

Noticias sobre sentimiento de mercado

By Acuity

56%

44%

298 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Bio-Techne Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 nov 2025, 22:36 UTC

Ganancias

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

Comparación entre iguales

Cambio de precio

Bio-Techne Corp previsión

Precio Objetivo

By TipRanks

21.99% repunte

Estimación a 12 Meses

Media 73.11 USD  21.99%

Máximo 80 USD

Mínimo 65 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bio-Techne Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

10 ratings

7

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

49.67 / 50.24Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

298 / 351 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat